四因子凝血酶原复合物与andexanet alfa逆转创伤性脑损伤的比较
该研究为2014至2021年35家创伤中心的回顾性分析,纳入头部简明损伤定级(AIS)>2且入院24小时内接受andexanet alfa或4F-PCC逆转的孤立性创伤性脑损伤患者,排除使用P2Y12抑制剂或头部以外AIS>2者。主要终点出院死亡率/临终关怀:andexanet alfa组15例(25.4%)vs 4F-PCC组49例(18.5%),OR 1.34(95%CI 0.67-2.71);严重并发症:5例(8.5%)vs 21例(7.9%),OR 1.01(95%CI 0.36-2.88)。作者结论为无法就两种药物对死亡率/临终关怀或严重并发症的治疗效应得出明确结论。
要点
- 孤立性TBI逆转抗凝:andexanet alfa组出院死亡率/临终关怀25.4%(15例)vs 4F-PCC组18.5%(49例),OR 1.34(95%CI 0.67-2.71),无显著差异。
- 严重TBI亚组(AIS头部4或5):andexanet alfa组28.6%(12例)vs 4F-PCC组28.7%(37例),OR 0.93(95%CI 0.40-2.16)。
- 严重院内并发症:andexanet alfa组8.5%(5例)vs 4F-PCC组7.9%(21例),OR 1.01(95%CI 0.36-2.88)。
- andexanet alfa组AIS头部5分比例更高(47.5% vs 26.1%;p<0.005),多因素逻辑回归已校正TBI严重程度与合并症。
适用人群与场景
- 2014至2021年35家创伤中心的孤立性创伤性脑损伤患者,头部AIS>2,且在入院24小时内接受andexanet alfa或4F-PCC逆转。
- 排除标准:使用P2Y12抑制剂,或头部以外区域AIS>2。
诊断标准与关键阈值
- 头部简明损伤定级(AIS)>2;严重TBI亚组定义为AIS头部4或5。
研究设计与关键结果
- 研究类型:35家创伤中心的回顾性综述,纳入2014至2021年数据;andexanet alfa组59例,4F-PCC组265例。
- 主要终点出院死亡率/临终关怀:andexanet alfa组15例(25.4%)vs 4F-PCC组49例(18.5%),OR 1.34(95%CI 0.67-2.71)。
- 严重TBI亚组(AIS头部4或5)出院死亡率/临终关怀:andexanet alfa组12例(28.6%)vs 4F-PCC组37例(28.7%),OR 0.93(95%CI 0.40-2.16)。
- 严重院内并发症复合终点:andexanet alfa组5例(8.5%)vs 4F-PCC组21例(7.9%),OR 1.01(95%CI 0.36-2.88)。
- andexanet alfa组AIS头部5分比例高于4F-PCC组(47.5% vs 26.1%;p<0.005)。
证据类型、等级与局限
- 证据类型:回顾性多中心研究(35家创伤中心)。
- 采用多因素逻辑回归校正合并症与TBI严重程度差异。
- 作者结论:无法就andexanet alfa与4F-PCC对死亡率/临终关怀或严重并发症的治疗效应得出明确结论。
对床旁实践的改变
- 作者结论未就andexanet alfa与4F-PCC的选择给出明确推荐;原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Andexanet alfa was approved in 2018 for reversal of direct oral anticoagulants but due to issues of cost and access, four-factor prothrombin complex concentrate (4F-PCC) continues to be used for this indication. The objective of this study is to evaluate outcomes of reversal with these agents in patients with isolated traumatic brain injuries (TBI).
METHODS: This is a retrospective review of 35 trauma centres from 2014 to 2021. Patients were included with an Abbreviated Injury Scale (AIS)>2 for head and having received andexanet alfa or 4F-PCC within 24 hours of admission. Patients were excluded if P2Y12 inhibitor use or AIS>2 outside of head. Primary outcome includes rate of mortality/hospice at hospital discharge. Secondary outcomes include a composite of serious hospital complications. A subgroup analysis of severe TBI patients (AIS head 4 or 5) was completed. Multivariable logistic regression was used to account for differences in comorbidities and TBI severity.
RESULTS: 4F-PCC was given to 265 patients with another 59 receiving andexanet alfa. Patients in the andexanet alfa group were more likely to have an AIS head score of 5 (47.5% vs 26.1%; p<0.005). After adjusting for severity of TBI and comorbidities with regard to tomortality/hospice, there were 15 (25.4%) patients in the andexanet alfa group and 49 (18.5%) in the 4F-PCC group (OR 1.34; 95% CI 0.67 to 2.71). This remained consistent when looking at severe patients with TBI with 12 (28.6%) andexanet alfa patients and 37 (28.7%) 4F-PCC patients (OR 0.93 (95% CI 0.40 to 2.16)). Severe hospital complications were also similar between groups with 5 (8.5%) andexanet alfa patients as compared with 21 (7.9%) 4F-PCC patients (OR 1.01; 95% CI 0.36 to 2.88).
CONCLUSION: There was no firm conclusion on the treatment effect in mortality/hospice or serious complications among isolated TBI patients reversed with 4F-PCC as compared with andexanet alfa.
参考来源
- Sadek E, Curtiss W, Andrews J, et al. Four-factor prothrombin complex concentrate versus andexanet alfa for the reversal of traumatic brain injuries. Emerg Med J. 2024. PMID: 38267194. doi:10.1136/emermed-2023-213229
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。